U.S. Markets open in 47 mins.

Hikma Pharmaceuticals PLC (HIK.L)


LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
1,666.00-5.00 (-0.30%)
As of 1:28PM BST. Market open.
People also watch
SHP.LAHT.LHL.LINF.LITRK.L
Interactive chart
Previous Close1,671.00
Open1,674.00
Bid1,664.00 x 16300
Ask1,666.00 x 34600
Day's Range1,643.00 - 1,676.80
52 Week Range1,573.00 - 2,703.00
Volume402,174
Avg. Volume847,782
Market Cap4B
Beta0.18
PE Ratio (TTM)25.17
EPS (TTM)66.2
Earnings DateAug 17, 2017
Dividend & Yield0.22 (0.87%)
Ex-Dividend Date2016-09-01
1y Target Est25.92
  • Financial Times6 days ago

    [$$] Hikma shares hit after cutting sales forecasts

    Shares in Hikma Pharmaceuticals fell 7 per cent in early trading on Friday after it cut sales forecasts following the US's decision last week to deny regulatory approval for its main pipeline drug. The ...

  • Reuters6 days ago

    Hikma cuts revenue forecast on generic Advair delay; shares sink

    Hikma Pharmaceuticals Plc lowered its full-year revenue forecast on Friday to reflect a delay in the launch of its generic asthma drug amid pricing pressures in the United States, sending its shares down to a three-year low. Earlier this month, the drugmaker said U.S. regulators decided not to approve its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair, citing "major" issues with the application. The company, which makes and markets branded and non-branded generic and injectable drugs, now expects full-year revenue to be in the range of $2 billion-$2.1 billion at constant currency, down from its earlier forecast of $2.2 billion.

  • TheStreet.com6 days ago

    Hikma Trims Full-Year Revenue Guidance After Advair Diskus Delay

    Hikma Pharmaceuticals lowered its full year revenue guidance Friday after the U.S. Food & Drug Administration expressed concern over its generic Advair Diskus product.